Fig. 1From: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studySwimlane plot of time to response, treatment duration, and duration of follow-up for efficacy-evaluable patients who achieved response in the mBCC cohort (a) and the laBCC cohort (b). laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinomaBack to article page